041830 - In Body Co., Ltd.

041830 Summary

Medical Devices

Stock Price & Overview

₩61,100 +1,500 (+2.52%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩61,100 ≈ US$44 · Market cap ₩0.8tn (≈ $588m)

041830 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	233.9	204.5	170.4	160.0	137.8	107.1	117.1	99.6	93.3	79.8	68.9
Cost of Revenue	52.9	46.2	37.9	38.9	36.5	29.7	30.8	26.7	23.8	22.0	19.5
Gross Profit	181.0	158.2	132.5	121.1	101.3	77.5	86.3	72.9	69.5	57.8	49.4
Selling, General & Administrative	144.3	121.5	94.1	80.4	65.5	58.4	58.6	49.3	44.6	35.8	29.4
Operating Income	36.8	36.7	38.3	40.7	35.9	19.1	27.6	23.7	24.9	22.0	20.0
Finance Income	6.4	8.8	6.3	5.1	3.2	1.7	1.5	1.5	1.4	0.5	0.7
Finance Costs	4.1	1.8	2.5	3.3	1.8	1.7	0.8	0.6	2.9	—	—
Pretax Income	38.6	43.9	44.6	42.5	39.3	20.7	28.2	24.6	23.4	20.8	20.8
Income Tax Expense	8.6	11.1	8.0	8.7	5.4	3.1	7.8	5.0	4.1	3.8	3.5
Net Income	30.0	32.7	36.6	33.8	34.0	17.6	20.4	19.6	19.3	17.0	17.3
Total Comprehensive Income	30.6	35.8	37.2	34.1	35.5	17.2	20.7	19.7	18.4	—	—

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	361.1	305.8	274.5	242.7	203.8	166.2	154.9	131.7	112.0	97.1	82.5
Current Assets	213.2	171.4	149.0	135.5	110.1	84.4	74.0	55.5	75.1	64.3	54.1
Cash & Cash Equivalents	52.4	31.0	22.3	21.6	18.6	17.0	14.4	9.6	11.2	10.3	5.6
Inventories	37.5	37.8	29.4	27.9	18.4	16.3	19.9	15.9	10.6	9.3	9.0
Trade Receivables	31.6	25.2	17.4	18.1	17.3	8.8	10.6	12.0	12.3	11.0	10.0
Non-current Assets	147.9	134.4	125.5	107.2	93.7	81.8	80.9	76.2	36.9	32.7	28.3
Property, Plant & Equipment	87.2	83.5	80.0	75.4	72.1	64.6	70.0	71.1	31.8	27.9	23.0
Intangible Assets	1.9	2.0	1.2	1.7	1.3	0.7	0.8	1.1	1.5	1.7	1.7
Total Liabilities	41.3	31.9	24.6	26.6	20.0	16.0	15.1	7.2	5.5	4.7	6.1
Current Liabilities	32.9	25.8	17.5	19.2	16.3	11.1	10.9	5.9	5.0	4.1	5.9
Non-current Liabilities	8.4	6.1	7.2	7.4	3.7	4.9	4.2	1.2	0.5	0.6	0.2
Total Equity	319.8	273.9	249.8	216.0	183.8	150.2	139.8	124.5	106.5	92.3	76.3
Share Capital	6.8	6.8	6.8	6.8	6.8	6.8	7.3	7.3	7.3	7.3	7.3
Retained Earnings	301.1	280.4	251.9	219.0	187.8	155.6	140.0	121.3	103.2	85.3	69.4

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	35.8	28.6	38.7	30.4	30.4	28.5	24.2	17.7	18.6	18.2	11.2
Cash from Investing Activities	-29.5	-5.7	-32.3	-22.0	-25.1	-16.3	-12.0	-17.7	-13.1	-12.6	-9.7
Purchase of Property, Plant & Equipment	6.9	6.3	7.5	5.4	11.3	1.7	3.1	40.9	5.3	7.6	7.3
Cash from Financing Activities	13.3	-15.1	-6.2	-5.3	-4.3	-9.2	-7.4	-1.7	-4.2	-1.1	-0.8
Dividends Paid	5.0	4.6	3.9	2.6	1.8	1.9	1.6	1.6	1.4	1.1	0.8
Net Change in Cash	19.6	7.8	0.2	3.1	1.0	3.0	4.8	-1.6	1.3	4.5	0.7

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	73.3	68.4	62.4	59.8	56.2	55.6	55.1	50.7	50.2	48.4
Cost of Revenue	14.3	17.0	13.4	15.1	11.0	13.3	13.1	10.3	11.1	11.7
Gross Profit	58.9	51.5	49.0	44.7	45.1	42.3	42.0	40.4	39.1	36.7
Selling, General & Administrative	41.2	38.4	39.5	34.8	34.7	35.3	34.5	30.6	29.7	26.7
Operating Income	17.7	13.0	9.5	9.8	10.4	7.0	7.5	9.8	9.4	10.0
Finance Income	3.5	5.1	2.0	1.2	1.0	2.2	4.7	0.1	2.1	1.9
Finance Costs	0.3	0.6	1.6	-1.0	2.8	0.7	0.3	0.7	0.5	0.3
Pretax Income	21.3	17.9	9.9	11.8	9.0	8.0	11.8	9.2	11.3	11.7
Income Tax Expense	6.8	1.6	3.5	2.4	1.6	1.2	3.4	1.8	3.1	2.9
Net Income	14.5	16.3	6.4	9.4	7.4	6.8	8.4	7.4	8.2	8.7
Total Comprehensive Income	15.6	18.7	7.3	10.8	5.5	7.0	11.0	6.6	8.7	9.5

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	388.4	381.1	361.1	318.3	301.4	309.6	305.8	303.6	296.9	298.2
Current Assets	234.8	230.3	213.2	176.2	164.6	172.6	171.4	171.5	166.9	171.6
Cash & Cash Equivalents	72.6	61.8	52.4	34.7	33.7	30.5	31.0	42.0	24.5	27.4
Inventories	43.9	41.9	37.5	37.7	36.2	37.9	37.8	35.3	34.6	30.5
Trade Receivables	38.2	33.8	31.6	31.2	26.7	25.5	25.2	23.0	24.8	32.1
Non-current Assets	153.7	150.9	147.9	142.2	136.8	137.0	134.4	132.1	129.9	126.6
Property, Plant & Equipment	88.4	87.4	87.2	87.0	83.8	83.4	83.5	82.5	81.8	80.7
Intangible Assets	1.7	1.8	1.9	1.8	1.9	2.0	2.0	1.1	1.2	1.3
Total Liabilities	41.9	50.6	41.3	36.3	31.2	36.2	31.9	33.2	33.1	43.4
Current Liabilities	35.2	43.5	32.9	28.5	25.0	29.9	25.8	25.6	25.5	35.5
Non-current Liabilities	6.7	7.1	8.4	7.8	6.2	6.4	6.1	7.6	7.5	7.9
Total Equity	346.5	330.6	319.8	282.0	270.1	273.4	273.9	270.4	263.8	254.8
Share Capital	6.8	6.8	6.8	6.8	6.8	6.8	6.8	6.8	6.8	6.8
Retained Earnings	323.5	309.4	301.1	294.6	285.0	277.4	280.4	271.8	264.4	256.1

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	7.6	9.8	13.7	9.0	5.6	7.4	6.1	8.1	6.4	8.0
Cash from Investing Activities	10.9	-1.3	-28.7	-9.1	12.7	-4.4	-9.2	10.4	-4.2	-2.6
Purchase of Property, Plant & Equipment	1.2	0.8	1.1	3.6	1.6	0.6	1.4	1.6	1.9	1.3
Cash from Financing Activities	-8.5	-1.5	31.1	0.5	-14.9	-3.4	-8.4	-0.8	-5.3	-0.5
Dividends Paid	—	—	0.0	0.0	—	—	0.0	0.0	—	—
Net Change in Cash	10.0	7.0	16.1	0.5	3.4	-0.5	-11.6	17.6	-3.2	4.9

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

041830 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	233.9	+14.4%	+13.5%	+16.9%	+13.0%
Operating income	36.8	+0.0%	-3.3%	+14.0%	+6.3%
Net income	30.0	-8.3%	-3.9%	+11.3%	+5.6%
EPS	₩2,224	-8.3%	-3.9%	+11.3%	+5.6%
Operating cash flow	35.8	+25.2%	+5.6%	+4.7%	+12.3%
Shareholders' equity	319.8	+16.8%	+14.0%	+16.3%	+15.4%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

041830 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	77.4%	77.4%	77.8%	75.7%	73.5%	72.3%
Operating margin	15.7%	18.0%	22.5%	25.4%	26.0%	17.8%
Net margin	12.8%	16.0%	21.5%	21.1%	24.7%	16.4%
Return on equity	10.1%	12.5%	15.7%	16.9%	20.4%	12.1%
Return on assets	9.0%	11.3%	14.1%	15.2%	18.4%	10.9%
Operating cash flow / revenue	15.3%	14.0%	22.7%	19.0%	22.0%	26.6%
Capex / revenue	3.0%	3.1%	4.4%	3.4%	8.2%	1.6%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 041830

Symbol	Last Price
096530Seegene, Inc.	₩31,900 +1.1%
491000Livs Med, Inc.	₩34,500 +3.6%
445680Curiox Biosystems Co., Ltd.	₩47,650 -1.5%
458870Seers Co., Ltd.	₩21,350 +3.1%
137310SD Biosensor	₩6,160 -0.3%
377740Bio Note, Inc.	₩4,790 -0.2%
340570T & L Co., Ltd.	₩29,650 +1.2%
099190i-SENS, Inc.	₩16,470 +0.0%
336570WON Tech Co., Ltd.	₩4,905 +0.9%
174900Ab Clon, Inc.	₩21,600 +5.9%

Compare all 13 in Medical Devices

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.